Office of Genomics and Precision Public Health, Office of Science, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Office of Genomics and Precision Public Health, Office of Science, Centers for Disease Control and Prevention, Atlanta, GA, United States of America; Tanaq Support Services, LLC, Atlanta, GA, United States of America.
Clin Immunol. 2022 Oct;243:109097. doi: 10.1016/j.clim.2022.109097. Epub 2022 Aug 13.
A better understanding of COVID-19 in people with primary immunodeficiency (PI), rare inherited defects in the immune system, is important for protecting this population, especially as population-wide approaches to mitigation change. COVID-19 outcomes in the PI population could have broader public health implications because some people with PI might be more likely to have extended illnesses, which could lead to increased transmission and emergence of variants. We performed a systematic review on COVID-19-associated morbidity and mortality in people with PI. Of the 1114 articles identified through the literature search, we included 68 articles in the review after removing 1046 articles because they were duplicates, did not involve COVID-19, did not involve PI, were not in English, were commentaries, were gene association or gene discovery studies, or could not be accessed. The 68 articles included outcomes for 459 people with PI and COVID-19. Using data from these 459 people, we calculated a case fatality rate of 9%, hospitalization rate of 49%, and oxygen supplementation rate of 29%. Studies have indicated that a number of people with PI showed at least some immune response to COVID-19 vaccination, with responses varying by type of PI and other factors, although vaccine effectiveness against hospitalization was lower in the PI population than in the general population. In addition to being up-to-date on vaccinations, current strategies for optimizing protection for people with PI can include pre-exposure prophylaxis for those eligible and use of therapeutics. Overall, people with PI, when infected, tested positive and showed symptoms for similar lengths of time as the general population. However, a number of people with X-linked agammaglobulinemia (XLA) or other B-cell pathway defects were reported to have prolonged infections, measured by time from first positive SARS-CoV-2 test to first negative test. As prolonged infections might increase the likelihood of genetic variants emerging, SARS-CoV2 isolates from people with PI and extended illness would be good candidates to prioritize for whole genome sequencing.
更好地了解原发性免疫缺陷(PI)人群中的 COVID-19,对于保护这一人群非常重要,尤其是在全人群缓解措施发生变化的情况下。PI 人群中的 COVID-19 结果可能具有更广泛的公共卫生意义,因为一些 PI 患者可能更容易出现长期疾病,这可能导致传播增加和变异出现。我们对 PI 人群中与 COVID-19 相关的发病率和死亡率进行了系统评价。通过文献检索确定了 1114 篇文章,经过去除 1046 篇重复文章、不涉及 COVID-19、不涉及 PI、非英语、评论、基因关联或基因发现研究或无法获取的文章,我们在综述中纳入了 68 篇文章。这 68 篇文章包括 459 名患有 COVID-19 的 PI 患者的结果。使用这些 459 名患者的数据,我们计算出病死率为 9%,住院率为 49%,氧疗率为 29%。研究表明,许多 PI 患者对 COVID-19 疫苗至少有一定的免疫反应,反应因 PI 类型和其他因素而异,尽管 PI 人群中疫苗对住院的有效性低于一般人群。除了及时接种疫苗外,目前优化 PI 患者保护的策略还可以包括对符合条件的患者进行暴露前预防以及使用治疗药物。总的来说,PI 患者在感染后与一般人群一样,检测结果呈阳性并出现症状的时间相似。然而,据报道,一些患有 X 连锁无丙种球蛋白血症(XLA)或其他 B 细胞途径缺陷的患者的感染时间延长,即从首次 SARS-CoV-2 检测阳性到首次检测阴性的时间。由于延长的感染可能会增加遗传变异出现的可能性,因此来自 PI 患者和延长疾病的 SARS-CoV2 分离株将是优先进行全基因组测序的良好候选物。